medigraphic.com
ISSN 1816-8450 (Impreso)

2019, Número 3

<< Anterior Siguiente >>

Geroinfo 2019; 14 (3)


Tratamiento oncoespecífico en pacientes ancianos con cáncer de pulmón, mama y linfoma

Mir EYL, Rodríguez RJE, Martínez ELY, Carvajal AML, Medina PVM

Idioma: Español
Referencias bibliográficas: 49
Paginas:
Archivo PDF: 226.70 Kb.


RESUMEN

En Cuba, el envejecimiento poblacional se ha convertido en un problema de salud. El país cuenta con un porcentaje de adultos mayores de casi 21 %, pero se estima que para el 2025 uno de cada cuatro cubanos tendrá más de 60 años. La esperanza de vida es otro aspecto medular. En nuestro país, de cada 100 personas que nacen, se espera que 83 de ellos estén vivos a los 60 años. El cáncer es una de las principales causas de muerte en Cuba desde 1958. Los mayores de 60 años contribuyen al 66.8 % de todos los nuevos casos de cáncer y al 78.8 % de todas las muertes por cáncer. La siguiente revisión tiene como objetivo profundizar en el tratamiento multidisciplinario del paciente geriátrico, específicamente con los diagnósticos de cáncer de pulmón, mama y linfoma, con el fin de conocer las características que permitan individualizar el manejo terapéutico en este grupo etario.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gálvez-Cano, Chávez-Jimeno, H, Aliaga Díaz, Med Exp Salud Pública. 2016; 33(2):321-7

  2. Rosas-Carrasco O, González-Flores E, Brito-Carrera, A M., Vázquez-Valdez, O. E., Peschard-Sáenz, E., Gutiérrez-Robledo L.M. et al. Evaluación de la comorbilidad en el adulto mayor Revista Médica del Instituto Mexicano del Seguro Social, vol. 49, núm. 2, marzo-abril, 2011, pp. 153-162

  3. United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision. New York: United Nations. 2015.

  4. Envejecimiento y población en Cuba. A partir del Censo de Población y Viviendas de 2012 La Habana, Cuba, Editorial de Ciencias Sociales; 2016:62- 72.

  5. Rodríguez G, Albizu-Campos JC. La población de Cuba hoy. Rev Nov Pob. 2015;11. (22)

  6. Vega Hernández M. Tendencia de la fecundidad en Cuba, sus principales causas y consecuencias. Rev Cubana Salud Pública. 2014;40(2)

  7. Collazo Ramos, M Calero Ricardo J.R Algunas características del envejecimiento poblacional en cuba Medicent Electrón. 2016 oct. -dic. ;20(4)

  8. Naranjo Hernández Y, Figueroa Linares M, Cañizares Marín R. Envejecimiento poblacional en Cuba; Gaceta Médica Espirituana Univ. Ciencias Médicas. Sancti Spíritus Vol.17, No. 3 (2015).

  9. Ministerio de Salud Pública, República de Cuba. Anuario Estadístico de Salud. La Habana; 2017.

  10. David B Reuben D, MD, Given J:Comprehensive geriatric assessment. Up to date: Oct 19, 2018.

  11. Balducci L, Hardy CL, Lyman GH: Hemopoietic reserve in the older cancer patients: clinical and economic considerations. Cancer Control 2000; 7:539-547.

  12. Dumic,I, Nordin T Jecmenica M, Stojkovic Lalosevic M, Milosavljevic T Milovanovic T:Gastrointestinal Tract disorders in older age; Hindawi volume Volume 2019 |Article ID 6757524 |

  13. Meyerhardt Ja, Catalano PJ, Haller DG Macdonald JS, Benson AB 3rd, Fuchs CS Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol,2003;21:433-440.

  14. Federico Venuta, Daniele Diso, Onorati M, Anile M, S Mantovani S, Erino A. Rendina: Lung cancer in elderly patients. J Thorac Dis.2016 Nov;8(suppl11): 908-914

  15. Gosain R, Pollock YY, Jain D. Age-related Disparity: Breast Cancer in the Elderly. Curr Oncol Rep 2016; 18:69

  16. Yang JF, Lee MS, Lin CS, Chao HL, Chen CM, Lo CH, et al: Long-Term Breast Cancer Patient Outcomes After Adjuvant Radiotherapy Using Intensity- Modulated Radiotherapy or Conventional Tangential Radiotherapy. Medicine (Baltimore). 2016;95: 3113.

  17. Shlomit Strulov S, MD .Trevor A. Jolly, Jones E MD, PhD Hyman B: Cancer 2018.Oncology Journal. Breast cancer 32(2):58-63

  18. Benjamin D, Belinda E Kiel: Trastuzumab use in older patients with HER-2 positive metastatic breast cancer: Outcomes and treatment patterns in a whole of population Australian cohort 2003-2015. BMC Cancer. 2019; 19: 909.

  19. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21:4524-31

  20. Sud S, Lai P, Zhang T, Clemons M1, Wheatley-Price P : Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and older. J Geriatr Oncol 2015, 6:395-400.

  21. M.D. Vincent, D. Breadner, M.C. Cripps, D.J. Jonker, P. Klimo, J.J. Biagi, et al: Phase I/II Trial of dose reduced capecitabine in elderly patients with advanced colorectal cancer. Curr. Oncol 2017 Aug, 24 (4): 261-268

  22. Bertelson CL, Ji L, Garcia AA , Russell C, Spicer D, Garcia A, Richard Sposto R: Efficacy of very-low-dose capecitabine in metastatic breast cancer. Am J Hematol Oncol 2015 11:20-30.

  23. Biganzoli L1, Aapro M2, Loibl S3, Wildiers H4, Brain E: Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer treatment Reviews February 2016 Vol 43. 19-26.

  24. Lichtman SM, Hurria A, Cirrincione CT, et al: Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: Combined analysis of CALGB 9342 and 9840. Ann Oncol 2012; 23:632-638.

  25. Garrido ML, Morago AJ, Rovira PS, Olarte PE, Sánchez CP, Sánchez LM: Experience with eribulin in the treatment of elderly women with metastatic breast cancer: case studies. Future Oncol. 2018 Mar;14(7s):21-27.

  26. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 1;20(3):719-26

  27. Lidziisa Mao, Kasturi Mondal: A comparative study on quality of life of older adults. Indian Journal of continuing Nursing Education. 2019 | Volume: 20 | Issue : 1 | Page : 73-77

  28. R. Voumard, E. Rubli Truchard: Geriatric palliative care: a view of its concept, challenges and strategies; BMC Geriatr. 2018; 18: 220.

  29. Noone A, Howlader N, Krapcho M,et al.SEER Cancer Statistics Review,1975- 2015,based on November 2017 SEER data submission, posted to the SEER web site, april 2018.Bethesda, MD: National cancer Institute;2018

  30. Jemal A, Miller KD, Ma J, Siegel RL, Fedewa SA, Islami F et al: Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018;378(21):1999–2009

  31. Au J, el-Oakley R, Cameron EW. Pneumonectomy for bronchogenic carcinoma in the elderly. Eur. J Cardiothorac. Surg. 1994; 8:247–50

  32. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001; 56:628–38.

  33. Roviaro G, Varoli F, Nucca O, Vergani C, Maciocco M: Videothoracoscopic approach to primary mediastinal pathology. Chest 2000; 117:1179–83

  34. Malene Stochkel, Dorte Schou: Fractionated palliative thoracic radiotherapy in non-small cell lung cancer. BMC palliative cancer 17, article number:15(2018)

  35. Annals of Oncology (2018) 29 (suppl_9):139-142.

  36. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ et al: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res2009; 15:5267-5273

  37. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300.

  38. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH: Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018 Mar;142(3):321-346

  39. Chen RL, Zhao J, Zhang XC, Lou NN, Chen HJ, Yang X et al: Rizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. BMC Cancer. 2018 Nov 26;18(1):1171.

  40. National Cancer Institute. Cancer stat facts: non-Hodgkin lymphoma (2017).Google Scholar

  41. Jeff Minerd, Clinical Challenges: Aggressive Lymphomas in Elderly Patients Age is not always a limit for intensive therapy. Hematol oncol. Contributing Writer, MedPage 2018 June 11

  42. Catherine Thieblemont, Sophie Bernard, Thierry Molina: Management of aggressive lymphomas in elderly patients Hematol Oncol 2017;35(51):49-53

  43. Pfreundschuh M, Schubert J, Ziepert M Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60).Lancet Oncol. 2008 Feb;9(2):105-16.

  44. Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C:Combination of ofatumumab and reduced dose CHOP for diffuse large B cell lymphomas in patients aged 80 years or older: Multicentre, single-arm.phase2 trial from the LYSA group. Lancet Haematol.46-55 2017:10.1016/2352-3026(16)30171-5

  45. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B: Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 8- years with diffuse large B-cell lymphoma: a multicentre, single arm, phase 2 trial Lancet Oncol 2011;12:460-468

  46. Patrick M. Reagan, MD, Allison Magnuson, DO, and Jonathan W. Friedberg, MD, MMS. Hodgkin Lymphoma in Older Patients. Physicians education Resource 2016

  47. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

  48. Mir R , Anderson J , Strauchen J, . Nissen N. I, Cooper M. R , Sameer R: Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer. 1993;71(5):1857-1866

  49. Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV et al: Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798-2804.




2020     |     www.medigraphic.com